StockTrendNews.com

		US Markets in: hrs min sec

Set StockTrendNews.com as your Homepage! - Click Here

Home About Us Subscribe Contact

StockTrendNews (STN) Exclusive: Enzon Pharmaceuticals Inc

Enter Symbol or Keywords

EBITDA Increases 27% for Enzon Pharmaceuticals

Stock Quote: (NasdaqNM:ENZN)

11/17/2009

7.76

+0.11

+1.44%

211,152

EBITDA Increases 27% for Enzon Pharmaceuticals

Last

Price Change

% Chg

Volume

New York, NY, November 17, 2009-Ebitda News reports that EBITDA for Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) for its quarter ended September 30, 2009 was $6,534,000, a 27% increase over the year earl ... read full story

Website Address:	www.enzon.com
Industry:	Bio-Pharma & Therapeutics

Most Recent STN Exclusives

11/04/2010

Cash Flow from Operations for SAP AG Reaches Nine Year High

11/04/2010

Macrovision Solutions' OPS Ranking of "2" Reiterated by StockDiagnostics.com

11/04/2010

Cash Flow from Operations for Pepco Holdings Reaches Four Year High

11/04/2010

Cash Flow from Operations Increases 151% for KLA-Tencor

11/04/2010

Seven Year High in Cash Flow from Operations for Dana Holding

11/04/2010

Public Service Enterprise's Cash Flow from Operations Increases 48%

11/04/2010

StockDiagnostics.com Reiterates Schlumberger Limited's OPS Ranking of "1"

11/04/2010

Free Cash Flow Turns Negative for Goodyear's Third Quarter

11/04/2010

Cash Flow from Operations for Waste Management Increases 17.7%

11/04/2010

Free Cash Flow for America Movil Reaches Three Year High

Interactive Chart: ENZN

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now

More STN Exclusives for: ENZN

08/23/2010

Enzon Pharmaceuticals' EBITDA Turns Negative for its Second Quarter

08/20/2010

Revenue for Enzon Pharmaceuticals Decreases by 16.77% even though Revenue for Biotech and Medical Products Industry Increases by 9.21% over Latest 12 Months

08/19/2010

OPS Ranking for Enzon Pharmaceuticals Upgraded by StockDiagnostics.com

... more ENZN exclusives

Other News Sources: ENZN

12/08/2011

Enzon Presents Data From Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer

11/12/2011

Enzon Presents Clinical and Preclinical Data on mRNA Antagonists at 2011 AACR-NCI-EORTC Meeting

11/03/2011

ENZN: Q3 EPS (19c) vs (14c) EPS -36% Y/Y

... more ENZN news from other sources

Daily Market Updates

02/03/2012

Markets Rally Today Following Strong January Jobs Report

U.S. markets rallied today following the release of a positive January employment report. The Nasdaq Composite hit at an 11-year high and the Dow closed at its highest level in 3 1/2 years after the report showed that the U.S. economy added 243,000 n ... read full story